Share on StockTwits

Portola Pharmaceuticals (NASDAQ:PTLA) CFO Mardi Dier sold 3,706 shares of the company’s stock on the open market in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $29.95, for a total transaction of $110,994.70. Following the completion of the sale, the chief financial officer now directly owns 16,118 shares of the company’s stock, valued at approximately $482,734. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of Portola Pharmaceuticals (NASDAQ:PTLA) traded down 1.65% on Thursday, hitting $29.87. 372,310 shares of the company’s stock traded hands. Portola Pharmaceuticals has a 1-year low of $19.59 and a 1-year high of $30.95. The stock’s 50-day moving average is $23.31 and its 200-day moving average is $25.04. The company’s market cap is $1.228 billion.

Portola Pharmaceuticals (NASDAQ:PTLA) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.75) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.72) by $0.03. The company had revenue of $2.40 million for the quarter, compared to the consensus estimate of $1.81 million. During the same quarter last year, the company posted ($12.94) earnings per share. Portola Pharmaceuticals’s revenue was down 23.8% compared to the same quarter last year. On average, analysts predict that Portola Pharmaceuticals will post $-3.44 earnings per share for the current fiscal year.

Portola Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who has limited or no approved treatment options.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.